Colorectal cancer: Complexities and challenges in managed care

Journal of Managed Care Pharmacy

Volumn 13, Issue 6 SUPPL. C, 2007, Pages

  Minkoff, Neil B ^a  

^a HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

Accelerated Approval; Antineoplastics; Colorectal cancer; Fast Track; Medicare; Priority Review; Reimbursement

Indexed keywords

ANTIDEPRESSANT AGENT; BEVACIZUMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; OXALIPLATIN; PANITUMUMAB; PLACEBO; PROTON PUMP INHIBITOR; SORAFENIB;

CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL TRIAL; COLORECTAL CANCER; DRUG COST; DRUG INFUSION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; KIDNEY CARCINOMA; MEDICAID; MEDICAL PRACTICE; MEDICARE; PATIENT CARE; POPULATION SIZE; QUALITY OF LIFE; REIMBURSEMENT; SHORT SURVEY; UNITED STATES;

EID: 35348934968     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s6-c.27     Document Type: Short Survey

References (14)

1. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-19.
2. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
3. Hearings Before the Subcommittee on Health of the House Committee on Ways and Means, 109th Cong. (July 13, 2006) (testimony of Herb B. Kuhn, director, Centers for Medicare & Medicaid Services, U.S. Dept. of Health and Human Services). Available at: http://waysandmeans.house.gov/hearings.asp? formmode=view&rid=5108. Accessed July 18, 2007.
4. eASCO Legislative Conference: NCI, FDA, and CMS outline projects to enhance the quality of cancer care. J Oncol Pract. 2005;1:1-3. Available at: http://jop.stateaffiliates-asco.org/NovemberIssue/149.pdf. Accessed January 17, 2007.
5. Drug Trend Report: Navigating the New Health Economy. Franklin Lakes, NJ: Merck-Medco Managed Care, LLC.;2004.
6. The Pharmaceutical Research and Manufacturers of America. New medicines in development. Available at: http://newmeds.phrma.org/. Accessed October 30, 2006.
7. Berenson A. Hope, at $4,200 a Dose. New York Times. October 1, 2006. Available at: http://www.nytimes.com/2006/10/01/business/yourmoney/01drug. html?ex=1317355200&en=7769a6e7aa9326d3&ei=5088&partner= rssnyt&emc=rss. Accessed November 1, 2006.
8. U.S. Food and Drug Administration. Oncology tools: Fast Track, Priority Review and Accelerated Approval. Available at: http://www.accessdata.fda.gov/ scripts/cder/onctools/Accel.cfm. Accessed October 1, 2006.
9. Druker BJ, Guilhot F, O'Brien SG, et al; and the IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17.
10. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835-40.
11. Tarceva [complete prescribing information]. San Francisco, CA;Genentech. November 2005. Available at http://www.gene.com/gene/products/information/ oncology/tarceva/insert.jsp. Accessed January 18, 2007.
12. Peeters M, Van Cutsem E, Siena S, et al. A Phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs. BSC alone in patients with metastatic colorectal cancer [abstract]. Proc Am Assoc Cancer Res. 2006;47:A CP-1.
13. Vectibix [package insert]. Thousand Oaks, CA; Amgen. 2006. Available at http://www.vectibix.com/prescribing_information/prescribing_information.html. Accessed March 18, 2007.
14. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592-96.